OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx is viewed positively because its business is shifting from lower-margin managed services and ad-style revenue toward a higher-margin, more programmatic healthcare software model embedded in EHR and eRx workflows. Despite 2Q26 revenue falling 30% year over year to $20.5M, EBITDA rose to $4.9M with a 24.1% margin, gross margin reached 76.5%, and free cash flow was $8.6M, while the company also moved to net cash after refinancing debt at about 6.5% and repaying $8.3M. Additional upside comes from DAAP growing 30% year over year, DeepIntent creating a second growth engine through the authenticated EHR network, and management maintaining 2026 EBITDA guidance even after revenue resets.

OptimizeRx is facing weakening fundamental demand as net revenue retention fell to 90% from 121% last year, TTM revenue per top-20 pharma manufacturer dropped 14% Y/Y to $2.7M, and the company lost revenue from one of its largest 2025 customers. Its business remains highly concentrated, with 54% of TTM revenue from the top 20 pharma manufacturers, three customers each above 10% of 2025 revenue, and roughly 62% of 2025 revenue dependent on just two eRx and EHR channel partners. At the same time, the shift away from lower-margin managed services, lingering internal-control remediation, and exposure to the May 2025 executive order, December 2025 CMS proposal, and broader IRA pricing pressure create meaningful near-term volatility and margin risk.